Atherosclerotic cardiovascular disease is a major health concern worldwide and requires effective preventive measures. Lp(a) (lipoprotein [a]) has recently garnered attention as an independent risk ...

The RNA inhibitor olpasiran significantly reduces a type of "bad cholesterol" that's associated with a high risk of ...

New research found that high levels of ‘good cholesterol’ in the blood were associated with an increased risk of glaucoma, an ...

A study published by researchers from the Sant Pau Research Institute (IR Sant Pau) and the Stroke Unit of Sant Pau Hospital in the Journal of Lipid Research provides new evidence on the essential ...

Roche announced its next generation assay received FDA 510(k) clearance for the measurement of lipoprotein(a) for assessment ...

Analysis by Mount Sinai researcher from First-of-its kind global trial could lead to future therapies to prevent deadly ...

Researchers developed an epigenetic editing approach to silence the PCSK9 gene, achieving long-term cholesterol reduction ...

ApoB is emerging as a crucial piece of the heart health puzzle, even as sophisticated machines whir and beep with promises of ...

Using hormone replacement therapy (HRT) to reduce cardiovascular risk during menopause remains a topic of debate. The ...

Findings of a new study suggest that the quality of LDL and HDL cholesterol, rather than their quantity, is more important in ...

The RNA inhibitor olpasiran significantly reduces a type of "bad cholesterol" that's associated with a high risk of cardiovascular events, according to results from an analysis by a Mount Sinai ...

Lerodalcibep is an adnectin-based, small protein-binding, third generation proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor.